BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

596 related articles for article (PubMed ID: 7664216)

  • 1. Modulation of the renin-angiotensin-aldosterone system and cough.
    Lacourcière Y; Lefebvre J
    Can J Cardiol; 1995 Aug; 11 Suppl F():33F-39F. PubMed ID: 7664216
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of modulators of the renin-angiotensin-aldosterone system on cough. Losartan Cough Study Group.
    Lacourcière Y; Brunner H; Irwin R; Karlberg BE; Ramsay LE; Snavely DB; Dobbins TW; Faison EP; Nelson EB
    J Hypertens; 1994 Dec; 12(12):1387-93. PubMed ID: 7706699
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association between cough and angiotensin converting enzyme inhibitors versus angiotensin II antagonists: the design of a prospective, controlled study.
    Lacourcière Y; Lefebvre J; Nakhle G; Faison EP; Snavely DB; Nelson EB
    J Hypertens Suppl; 1994 Jul; 12(2):S49-53. PubMed ID: 7965266
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of polymorphisms of the renin-angiotensin system and bradykinin B2 receptor with ACE-inhibitor-related cough.
    Mukae S; Itoh S; Aoki S; Iwata T; Nishio K; Sato R; Katagiri T
    J Hum Hypertens; 2002 Dec; 16(12):857-63. PubMed ID: 12522467
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Renin inhibitors, angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists: relationships between blood pressure responses and effects on the renin-angiotensin system.
    Schalekamp MA; Derkx FH; van den Meiracker AH
    J Hypertens Suppl; 1992 Dec; 10(7):S157-64. PubMed ID: 1291650
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peptides as targets for antihypertensive drug development.
    Hedner T; Sun X; Junggren IL; Pettersson A; Edvinsson L
    J Hypertens Suppl; 1992 Dec; 10(7):S121-32. PubMed ID: 1291647
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ACE inhibitors, angiotensin II antagonists and cough. The Losartan Cough Study Group.
    Ramsay LE; Yeo WW
    J Hum Hypertens; 1995 Nov; 9 Suppl 5():S51-4. PubMed ID: 8583482
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Angioedema associated with angiotensin II receptor antagonists: challenging our knowledge of angioedema and its etiology.
    Chiu AG; Krowiak EJ; Deeb ZE
    Laryngoscope; 2001 Oct; 111(10):1729-31. PubMed ID: 11801934
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cough with angiotensin converting enzyme inhibitors: how much of a problem?
    Fletcher AE; Palmer AJ; Bulpitt CJ
    J Hypertens Suppl; 1994 Jul; 12(2):S43-7. PubMed ID: 7965265
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Angiotensin II blockade compared with other pharmacological methods of inhibiting the renin-angiotensin system.
    Brunner HR; Nussberger J; Waeber B
    J Hypertens Suppl; 1993 Apr; 11(3):S53-8. PubMed ID: 8315521
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the effects of angiotensin receptor antagonist, angiotensin converting enzyme inhibitor, and their combination on regression of left ventricular hypertrophy of diabetes type 2 patients on recent onset hemodialysis therapy.
    Suzuki H; Kanno Y; Kaneko K; Kaneko M; Kotaki S; Mimura T; Takane H
    Ther Apher Dial; 2004 Aug; 8(4):320-7. PubMed ID: 15274684
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [AT1 angiotensin receptor inhibition as a new therapeutic possibility].
    Hunyady L; Nagy L
    Orv Hetil; 1997 Oct; 138(41):2583-90. PubMed ID: 9411327
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Angiotensin II antagonists versus ACE inhibitors in the treatment of raised blood pressure].
    Andersen RS; Christensen S
    Ugeskr Laeger; 2001 Dec; 163(50):7036-9. PubMed ID: 11794033
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Renal effects of angiotensin II receptor blockade and angiotensin-converting enzyme inhibition in healthy subjects.
    Burnier M; Brunner HR
    Exp Nephrol; 1996; 4 Suppl 1():41-6. PubMed ID: 9001896
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Angiotensin II type 1 receptor blockade: a novel therapeutic concept.
    Johnston CI
    Blood Press Suppl; 2000; 1():9-13. PubMed ID: 11059629
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of renin-angiotensin-aldosterone system inhibitors within the first eight to twelve weeks after renal transplantation.
    Jennings DL; Taber DJ
    Ann Pharmacother; 2008 Jan; 42(1):116-20. PubMed ID: 18094340
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An update on non-peptide angiotensin receptor antagonists and related RAAS modulators.
    Aulakh GK; Sodhi RK; Singh M
    Life Sci; 2007 Aug; 81(8):615-39. PubMed ID: 17692338
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The future role of losartan.
    Hansson L
    J Hum Hypertens; 1995 Nov; 9 Suppl 5():S55-8. PubMed ID: 8583483
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.